Diabetes Care, Vol 21, Issue 3 389-397, Copyright © 1998 by American Diabetes Association

ARTICLES

Prescription drug use and costs among diabetic patients in primary health care practices in Germany

W Rathmann, B Haastert, JM Roseman, FA Gries and G Giani
Department of Biometrics and Epidemiology, Diabetes Research Institute, Dusseldorf, Germany. rath@dfi.uni-duesseldorf.de

OBJECTIVE: To evaluate drug prescriptions and costs among diabetic patients in primary care practices in Germany. RESEARCH DESIGN AND METHODS: Computerized data on prescriptions and costs (drug company sales prices) were analyzed in 30,604 diabetic and 17,723 (5% random sample) nondiabetic patients from 362 primary care practices during 1994. Relative use ratios for drug groups were obtained from logistic regression models (odds ratio [OR] for diabetes) controlling for age, sex, and other covariates. Relative costs (diabetic:nondiabetic) were estimated by direct age and sex standardization. RESULTS: Diabetic patients had an increased prescription use for most drugs. A substantial increased use (OR > or = 1.4) was found for cardiovascular drugs, fibrates, gout medication, laxatives, and wound care products. Diabetic subjects (7.9% of all patients) accounted for 21% of total annual prescription costs in the practices. Total costs (U.S. dollars) per patient-year were threefold higher (diabetic patients $384; control subjects $123). After excluding antidiabetic agents and age- and sex-standardization, relative costs were still 1.5 times higher (P < 0.05). Diabetes treatment accounted for 24% of total costs in diabetic patients (insulin 12%; oral antidiabetics 6%). The most important cost factor was cardiovascular drugs (CVDs) (39%). Three CVD groups accounted for about 50% of total CVD costs in diabetic patients (ACE inhibitors 25%; Ca-antagonists 16%; nitrates 10%). CONCLUSIONS: Prescription use among diabetic patients in primary health care practices was predominantly increased for cardiovascular drugs and for treatment of diabetes-associated disorders. Diabetic patients accounted for over one-fifth of the total pharmacy costs in primary practices, indicating that diabetes is a major economic factor in drug use.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				W. Rathmann, B. Haastert, A. Icks, and G. Giani Trends in Outpatient Prescription Drug Costs in Diabetic Patients in Germany, 1994-2004 Diabetes Care, April 1, 2007; 30(4): 848 - 853. [Abstract] [Full Text] [PDF]

				W. Rathmann, K. Kostev, B. Haastert, A. Parashar, A. Varma, R. Garg, G. Y. Gandhi, V. M. Montori, S. E. Kahn, G. Viberti, et al. Glycemic Durability of Monotherapy for Diabetes N. Engl. J. Med., March 29, 2007; 356(13): 1378 - 1380. [Full Text] [PDF]

				J. Oliva, F. Lobo, B. Molina, and S. Monereo Direct Health Care Costs of Diabetic Patients in Spain Diabetes Care, November 1, 2004; 27(11): 2616 - 2621. [Abstract] [Full Text] [PDF]

				R. S. Weinstock, G. Hawley, D. Repke, B. L. Feuerstein, C. T. Sawin, and L. M. Pogach Pharmacy Costs and Glycemic Control in the Department of Veterans Affairs Diabetes Care, May 1, 2004; 27(suppl_2): B74 - B81. [Abstract] [Full Text] [PDF]

				S. A. Grover, L. Coupal, H. Zowall, C. M. Alexander, T. W. Weiss, and D. R.J. Gomes How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease? Diabetes Care, January 1, 2001; 24(1): 45 - 50. [Abstract] [Full Text]